Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether ciprofloxacin changes clinical remission compared with metronidazole (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with acute pouchitis
It is very uncertain whether ciprofloxacin changes adverse events compared with metronidazole (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in clinical relapse compared with purine antimetabolites (low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes radiologic relapse compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes health related quality of life compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Overall survival · nonmetastatic esophageal cancer
Chemoradiotherapy showed no clear difference in overall survival compared with chemoradiotherapy plus surgery (high certainty).
1 finding from 1 review
Freedom from locoregional relapse · nonmetastatic esophageal cancer
Chemoradiotherapy probably leads to lower freedom from locoregional relapse compared with chemoradiotherapy plus surgery (moderate certainty).
1 finding from 1 review
Quality of life · nonmetastatic esophageal cancer
1 finding from 1 review
Treatment‐related mortality · nonmetastatic esophageal cancer
Chemoradiotherapy may leads to higher treatment‐related mortality compared with chemoradiotherapy plus surgery (low certainty).
1 finding from 1 review
Use of salvage procedures for dysphagia · nonmetastatic esophageal cancer
Chemoradiotherapy may leads to lower use of salvage procedures for dysphagia compared with chemoradiotherapy plus surgery (low certainty).
1 finding from 1 review